DE60220422D1 - Substituierte pyrazoloverbindungen zur behandlung von entzündungen - Google Patents

Substituierte pyrazoloverbindungen zur behandlung von entzündungen

Info

Publication number
DE60220422D1
DE60220422D1 DE60220422T DE60220422T DE60220422D1 DE 60220422 D1 DE60220422 D1 DE 60220422D1 DE 60220422 T DE60220422 T DE 60220422T DE 60220422 T DE60220422 T DE 60220422T DE 60220422 D1 DE60220422 D1 DE 60220422D1
Authority
DE
Germany
Prior art keywords
sub
sup
compounds
inflammation
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60220422T
Other languages
English (en)
Other versions
DE60220422T2 (de
Inventor
Suzanne Metz
Michael Clare
Joyce Z Crich
Timothy J Hagen
Gunnar J Hanson
He Huang
Stephen J Houdek
Michael A Stealey
Michael L Vazquez
Richard M Weier
Xiangdong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of DE60220422D1 publication Critical patent/DE60220422D1/de
Application granted granted Critical
Publication of DE60220422T2 publication Critical patent/DE60220422T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60220422T 2001-09-19 2002-09-19 Substituierte pyrazol-verbindungen zur behandlung von entzündungen Expired - Fee Related DE60220422T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32329701P 2001-09-19 2001-09-19
US323297P 2001-09-19
US38322602P 2002-05-24 2002-05-24
US383226P 2002-05-24
PCT/US2002/029625 WO2003024936A1 (en) 2001-09-19 2002-09-19 Substituted pyrazolo compounds for the treatment of inflammation

Publications (2)

Publication Number Publication Date
DE60220422D1 true DE60220422D1 (de) 2007-07-12
DE60220422T2 DE60220422T2 (de) 2008-02-07

Family

ID=26983875

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220422T Expired - Fee Related DE60220422T2 (de) 2001-09-19 2002-09-19 Substituierte pyrazol-verbindungen zur behandlung von entzündungen

Country Status (10)

Country Link
US (1) US7211597B2 (de)
EP (1) EP1427706B1 (de)
JP (1) JP2005510466A (de)
AT (1) ATE363473T1 (de)
BR (1) BR0212617A (de)
CA (1) CA2460939C (de)
DE (1) DE60220422T2 (de)
ES (1) ES2286275T3 (de)
MX (1) MXPA04002682A (de)
WO (1) WO2003024936A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229762A1 (de) 2002-07-03 2004-01-22 Aventis Pharma Deutschland Gmbh Pyrazoloisoquinolinenderivaten zur Inhibierung von NFkappaB-induzierende Kinase
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
JP2006522824A (ja) * 2003-04-09 2006-10-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患を処置するために有用なβ−カルボリン
WO2005012301A1 (en) * 2003-07-03 2005-02-10 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivatives as kinase inhibitors
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP2206713A1 (de) 2004-04-09 2010-07-14 Millennium Pharmaceuticals, Inc. Für die Behandlung von Entzündlichen Krankenheiten Nützliche beta-Carbolinen
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
EP1778669A2 (de) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase-inhibitoren
AU2005273867B2 (en) * 2004-08-18 2010-12-23 4Sc Ag Benzothienopyridines for use as inhibitors of Eg5 kinesin
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006079645A1 (en) * 2005-01-27 2006-08-03 Nycomed Gmbh Novel indolopyridines , benzofuranopyridines and benzothienopyridines
JP2008528551A (ja) * 2005-01-28 2008-07-31 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング インドロピリジン、ベンゾフラノピリジン及びベンゾチエノピリジン
CN101203495B (zh) * 2005-06-23 2013-07-17 默沙东公司 作为受体酪氨酸激酶met抑制剂的苯并环庚三烯并吡啶化合物
US8207186B2 (en) * 2005-06-23 2012-06-26 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET
TW200738638A (en) * 2005-06-23 2007-10-16 Merck & Co Inc Tyrosine kinase inhibitors
AU2006266028B2 (en) 2005-06-30 2012-03-15 Smithkline Beecham Corporation Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007050383A2 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2624676A1 (en) * 2005-10-21 2007-05-03 Jongwon Lim Tyrosine kinase inhibitors
BRPI0710073A2 (pt) * 2006-02-22 2011-08-02 4Sc Ag indolopiridinas
KR101415354B1 (ko) * 2006-02-22 2014-07-04 4에스체 악티엔게젤샤프트 Ｅｇ5 키네신 조절제로서의 인돌로피리딘
UY30377A1 (es) * 2006-06-02 2008-01-02 Elan Pharm Inc Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
TW200813021A (en) * 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
AU2007274283A1 (en) * 2006-07-13 2008-01-17 4Sc Ag Benzopyranopyrazoles
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
WO2010049366A1 (en) * 2008-10-27 2010-05-06 Glaxo Group Limited Tricyclic compounds as glutamate receptor modulators
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2904119B1 (de) 2012-10-02 2020-06-17 The General Hospital Corporation d/b/a Massachusetts General Hospital Verfahren für mit dem dna-erfassungspfad assoziierten leiden
JP6625973B2 (ja) 2013-06-24 2019-12-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのピラゾール化合物及びその使用
WO2015196335A1 (en) * 2014-06-23 2015-12-30 Tocopherx, Inc. Pyrazole compounds as modulators of fshr and uses thereof
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US11345710B2 (en) * 2017-07-10 2022-05-31 Impact Therapeutics (Shanghai), Inc Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
WO2024044778A2 (en) * 2022-08-26 2024-02-29 Celmatix Inc. Novel modulators of fshr and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
US4678499A (en) * 1985-03-11 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
JPS63166588A (ja) * 1986-12-27 1988-07-09 Kanzaki Paper Mfg Co Ltd クロメノ化合物およびクロメノ化合物を用いた感熱記録体
US4816467A (en) * 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use
GB8814587D0 (en) 1988-06-20 1988-07-27 Erba Carlo Spa Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation
GB2227741B (en) 1989-02-06 1992-08-05 Erba Carlo Spa Condensed 3-oxo-propanenitrile derivatives and process for their preparation
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
US5260328A (en) * 1989-04-06 1993-11-09 Farmitalia Carlo Erba Srl Phenyl-indenopurazol 3-oxo-propanamide derivatives useful in the treatment of rheumatoid arthritis
GB8916290D0 (en) * 1989-07-17 1989-08-31 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5886016A (en) * 1995-09-15 1999-03-23 G.D. Searle & Co. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
EP0892791B1 (de) * 1996-04-12 2003-03-05 G.D. Searle & Co. N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULPHONYLPROPYLAMID und sein NATRIUMSALZ ALS PRO-PHARMAKON VON COX-2 INHIBITOREN
DE69918542T2 (de) 1998-04-30 2005-08-18 Abbott Gmbh & Co. Kg Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
EP1142889A1 (de) 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazolderivate als entzündungs-/schmerzhemmende Mittel

Also Published As

Publication number Publication date
MXPA04002682A (es) 2004-06-18
ES2286275T3 (es) 2007-12-01
ATE363473T1 (de) 2007-06-15
EP1427706B1 (de) 2007-05-30
US20030114432A1 (en) 2003-06-19
EP1427706A1 (de) 2004-06-16
CA2460939A1 (en) 2003-03-27
JP2005510466A (ja) 2005-04-21
WO2003024936A1 (en) 2003-03-27
US7211597B2 (en) 2007-05-01
DE60220422T2 (de) 2008-02-07
CA2460939C (en) 2008-07-29
BR0212617A (pt) 2005-02-09

Similar Documents

Publication Publication Date Title
DE60220422D1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
MXPA04000622A (es) Pirazolilcarboxanilidas como funguicidas.
ATE311386T1 (de) Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit
ATE343388T1 (de) Pde-v hemmer zur behandlung von morbus parkinson
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
ATE396988T1 (de) Chinolin- und chianzolinderivate zur behandlung von tumoren
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
GEP20053590B (en) Phenyl Heterocyclyl Ether Derivatives as Serotonin Re-Uptake Inhibitors
ATE179168T1 (de) Substituierte spiroverbindungen zur behandlung von entzündungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE419238T1 (de) Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
BG106846A (en) Novel heteroaryl derivatives, their preparation and use
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee